|Bid||180.960 x 1200|
|Ask||181.040 x 200|
|Day's Range||180.800 - 181.600|
|52 Week Range||135.010 - 182.520|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.24%|
The legislative move has led to the return of Trump trade and investors are cashing in on the opportunity with ETFs that are deemed to gain most on tax reforms.
In a recent post by Project Syndicate, Nobel laureate and Yale economics professor Robert Shiller said that stock markets (SPY) are dangerously close to a bear market. Professor Shiller’s cyclically adjusted…...
Key U.S. stock indexes were slightly higher Tuesday as Apple rose but some other big-cap techs gave up early gains.
Key U.S. stock indexes were lower in the stock market today as Apple and other techs fell under pressure.
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.
In 1Q17, the Advisory Board (ABCO) reported revenues of ~$194.1 million, which was higher than its guidance of $185 million–$190 million but ~0.7% lower YoY.
According to Reuters, on June 30, 2017, all of the sell-side analysts tracking Flotek Industries (FTK) have rated the stock a “buy” or some equivalent.
A large-cap blend ETF led U.S. diversified funds in June, but small-cap names dominated the rest of the list.
As of June 20, 2017, Papa John’s was trading at a forward PE multiple of 24.8x—compared to 27.3x before the announcement of its 1Q17 earnings.
Major U.S. index ETFs were slightly higher Friday, as the Nasdaq, Dow Jones industrial average and S&P 500 powered to new highs.
Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.
This article is part of a regular series of thought leadership pieces from some of the more influential ETF strategists in the money management industry. Today's article is by Mack Courter, f ounder of Courter Financial in Bellefonte, Pennsylvania .
By Bruce Aronow , James MacGregor , Shri Singhvi , Samantha S. Lau April 10, 2017 Though the “Trump bump” helped, the year-old winning streak in smaller stocks owes far more to the spirited US economy. This rally has firepower, but we’d be choosy in ...
Analysts expect Shake Shack (SHAK) to post EPS of $0.50 in 2017, which represents 8.7% growth from its 2016 EPS of $0.46.